Both loss of DRD1 expression and methylation of the DRD1 promoter are predictive markers of disease progression, and thus, DRD1 promoter methylation may be a negative predictive biomarker in NSCLC patients. The gene discussed is DRD1; the disease is non-small cell lung carcinoma.